TSH Suppression for Papillary Thyroid Cancer: A Physician Survey Study

CONCLUSION: Many patients with low-risk thyroid cancer continue to be treated with suppressive doses of thyroid hormone, emphasizing the need for more high quality research to guide thyroid cancer management, as well as better understanding of barriers that hinder guideline adoption.PMID:33779292 | DOI:10.1089/thy.2021.0033

Source: Thyroid : official journal of the American Thyroid Association - March 29, 2021 Category: Endocrinology Authors: Maria Papaleontiou Debbie Chen Mousumi Banerjee David Reyes-Gastelum Ann S Hamilton Kevin C Ward Megan R Haymart Source Type: research